Empagliflozin as add-on to metformin in people with Type 2 diabetes

Aims To investigate the long‐term efficacy and safety of empagliflozin as add‐on to metformin in people with Type 2 diabetes. Methods Of 637 participants treated with empagliflozin 10 mg, empagliflozin 25 mg, or placebo once daily for 24 weeks, 463 (72.7%) were treated in a double‐blind extension trial for ≥ 52 weeks. Prespecified exploratory endpoints included changes from baseline in HbA1c, weight and blood pressure at week 76. Results Compared with placebo, adjusted mean changes from baseline in HbA1c (overall baseline mean ± sd 63 ± 9 mmol/mol [7.9 ± 0.9%]) were −7 mmol/mol [(−0.6%) 95% CI −8, −5 mmol/mol (−0.8, −0.5%); P